CD6 and lobular neoplasia: Comparatively, assessment of the alternate CD6 ligand, CD318, showed urine levels that were below detection (data not shown) while serum levels did not distinguish between patients with active LN versus patients with active, nonrenal disease or inactive SLE (Supplemental Figure 2A).